MASLD / Liver Research Metabolic dysfunction-associated steatotic liver disease is under Phase 3 evaluation
The clinical spectrum of MASLD spans from simple steatosis, which is often benign and potentially reversible, to metabolic dysfunction-associated steatohepatitis (MASH), a progressive and inflammatory condition that may lead to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (2, 3)
doi:10.1136/bmj-2023-076410 14
16 Figure 3: Risk of OACs in patients on GLP-1s versus patients on insulin Conclusion GLP-1s, initially developed to help manage and treat diabetes and later used to treat obesity, are now showing significant potential to help prevent and treat CVD, mental health disorders, liver and kidney disorders, neurodegenerative disorders, addiction disorders, and cancer
First Four Weeks Initial Retatrutide effects typically appear within the first week of dosing
It slows gastric emptying (leading to early satiety), increases insulin secretion, and signals the brain to reduce appetite
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
